Incomplete Neoadjuvant Radiation Linked to Worse Outcomes for Rectal Cancer
Completing a course of preoperative radiotherapy prior to undergoing surgical resection for rectal cancer was associated with improved survival compared with patients who had an incomplete course of radiotherapy. (Source: CancerNetwork)
Source: CancerNetwork - March 10, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Colorectal Cancer Gastrointestinal Cancer News Radiation Oncology Source Type: news
More guidelines, uniformity in RT needed following chemotherapy, surgery in breast cancer
(American Society for Radiation Oncology) Wide variability exists in radiation treatment decisions following neoadjuvant chemotherapy and surgery for breast cancer, according to a review of the American College of Surgeons Oncology Group Z1071, a prospective trial. ACOSOG is now part of the Alliance for Clinical Trials in Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 7, 2016 Category: Global & Universal Source Type: news
Neoadjuvant Radiation Renders Pancreatic Tumors Resectable
(MedPage Today) -- Dose escalation study finds improved overall survival with no increase in toxicity (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 14, 2015 Category: Gastroenterology Source Type: news
ASTRO Issues Guideline on Radiation Therapy for Rectal Cancer
Neoadjuvant RT recommended for stage II to III rectal cancer; RT should be performed preoperatively (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Radiology, Journal, Source Type: news
Clinical practice guidelines address multimodality treatment for esophageal cancer
New clinical practice guidelines for treating cancer of the esophagus and gastroesophageal junction (area where the esophagus meets the stomach) have been released. The guidelines include nine evidence-based recommendations that address issues related to multimodality care, including neoadjuvant therapy (chemotherapy and radiation therapy given prior to surgery). The goal of this therapy is to reduce the extent of cancer before an operation to maximize the chance of obtaining a cure. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 30, 2014 Category: Science Source Type: news
Blood test for VEGF-A, TGF-B1 could help determine treatment options for esophageal cancer patients
(American Society for Radiation Oncology) A blood test may be beneficial in indicating neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 14, 2014 Category: Cancer & Oncology Source Type: news
New Data on Neoadjuvant Chemo and Breast Cancer RecurrenceNew Data on Neoadjuvant Chemo and Breast Cancer Recurrence
If breast cancer specialists could identify which patients were unlikely to experience disease recurrence after neoadjuvant chemotherapy, radiation therapy might be avoided. A new study has insights. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 5, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Cerulean starts patient dosing in Phase Ib/II combination trial of CRLX101 to treat rectal cancer
US-based Cerulean Pharma has dosed its first patient in a Phase Ib/II trial of CRLX101 in combination with chemotherapy and radiation in neoadjuvant rectal cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - March 19, 2014 Category: Pharmaceuticals Source Type: news
In intermediate risk prostate cancer, fewer weeks of hormone therapy before radiation reduces side effects
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the American Society for Radiation Oncology's (ASTRO) 55th Annual Meeting. The study confirmed a disease-specific-survival (DSS) rate of 95 percent when patients received fewer weeks of neoadjuvant (NEO) total androgen suppression (TAS)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 25, 2013 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news
Radiation Therapy and Esophageal CancerRadiation Therapy and Esophageal Cancer
Neoadjuvant chemoradiotherapy followed by surgical resection is the current standard of care for localized cancer of the esophagus. What's on the horizon? Cancer Control: Journal of the Moffitt Cancer Center (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - June 3, 2013 Category: Radiology Tags: Hematology-Oncology Journal Article Source Type: news
CT Texture Analysis Of Tumors May Be A Valuable Biomarker In Localized Esophageal Cancer
CT texture analysis of primary tumors may be a potential imaging biomarker in localized esophageal cancer following neoadjuvant chemotherapy, according to research presented at the 2013 Cancer Imaging and Radiation Therapy Symposium. This Symposium is sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North American (RSNA)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 12, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Tumoral Texture Features May Be A Valuable Biomarker In Localized Esophageal Cancer
CT texture analysis of primary tumors may be a potential imaging biomarker in localized esophageal cancer following neoadjuvant chemotherapy, according to research presented at the 2013 Cancer Imaging and Radiation Therapy Symposium. This Symposium is sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North American (RSNA)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 12, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
CT texture analysis of tumors may be a valuable biomarker in localized esophageal cancer
(American Society for Radiation Oncology) CT texture analysis of primary tumors may be a potential imaging biomarker in localized esophageal cancer following neoadjuvant chemotherapy, according to research being presented at the 2013 Cancer Imaging and Radiation Therapy Symposium. This Symposium is sponsored by the American Society for Radiation Oncology and the Radiological Society of North America. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 8, 2013 Category: Global & Universal Source Type: news
Summaries: International Kidney Cancer Symposium
Conclusion: there is no increased risk of doing the lymph node dissection early on.
Dr. Eggener-CON
Basics
Lymph node dissections rarely done, even for large tumors, because there is no proven therapeutic or staging benefit for low risk patients. A Mayo study revealed no data showing therapeutic benefit in high risk patients. For clinically node negative high risk patients, there is staging value but no proven therapeutic benefit.
Rate of positive nodes is associated with stage and grade; the higher the stage and grade, the more likely there will be positive nod...
Source: Kidney Cancer Association - November 29, 2011 Category: Urology & Nephrology Source Type: news
Summaries: International Kidney Cancer Symposium
Conclusion: there is no increased risk of doing the lymph node dissection early on. Dr. Eggener-CON
Basics
Lymph node dissections rarely done, even for large tumors, because there is no proven therapeutic or staging benefit for low risk patients. A Mayo study revealed no data showing therapeutic benefit in high risk patients. For clinically node negative high risk patients, there is staging value but no proven therapeutic benefit.
Rate of positive nodes is associated with stage and grade; the higher the stage and grade, the more likely there will be positive nodes. A tumor> 10 cm w...
Source: Kidney Cancer Association - November 29, 2011 Category: Urology & Nephrology Source Type: news
